Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics (ASX:NUZ) has confirmed this week.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
“This is a very positive result,” Dr Michael Thurn told HotCopper, declaring on the company’s news: “We have been able to show NUZ-001 may have the potential to be a treatment for Alzheimer’s disease and Parkinson’s disease.”
“As you know, they are diseases that are becoming more and more important in aging populations so these results really set us up to look at these two indications going forward.”
NUZ has been trading 4.7% lower on Monday and is now selling at 10cps.
Join the discussion. See what HotCopper users are saying about Neurizon Therapeutics and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。